Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company, has announced positive topline results from its Phase 2 Explore-CKD trial involving lorundrostat. This trial evaluated the safety and efficacy of a 25 mg dose of lorundrostat in subjects with hypertension and comorbid chronic kidney disease (CKD). The trial met its primary endpoint, demonstrating a placebo-adjusted reduction in systolic blood pressure of 7.5 mmHg and a significant reduction in the urine albumin-to-creatinine ratio by 31%. Lorundrostat also showed a favorable safety and tolerability profile. These results have been presented, and a conference call discussing the findings was held on June 17, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.